Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    84
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC01 NEOOPRAZOLE G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 407,184 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
C03CA01 FURESIX 40 G Furosemide - 40mg 40mg Tablet 166,381 L.L
C10AA05 TORVALIP 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 972,686 L.L
D07CC01 TOPIZONE G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 216,359 L.L
G04BE03 PLEASE G Sildenafil - 50mg 50mg Film, orally soluble 2,687,685 L.L
J01CR02 AMOCLAN FORTE G Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg 625mg Tablet 170,668 L.L
J01GB03 GENTAMICINE PANPHARMA G Gentamicin (sulfate) - 80mg/2ml 80mg/2ml Injectable solution 721,643 L.L
L01EA02 DALEUBIN G Dasatinib - 20mg 20mg Tablet, film coated 82,387,571 L.L
L02BA03 FUXRAN G Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution 39,382,304 L.L
M01AB05 CLOREN ADULTS G Diclofenac sodium - 100mg 100mg Suppository 598,970 L.L
N01AB06 ISOFLURANE HIKMA G Isoflurane - Volatil liquid 1,583,046 L.L
P01AB01 METROGYL G Metronidazole benzoate - 200mg/5ml 200mg/5ml Powder for suspension 500,867 L.L
R05DA09 DIACOL G Dextromethorphan HBr - 27mg/15ml 27mg/15ml Syrup 517,379 L.L
A02BC01 OMEDAR G Omeprazole - 20mg 20mg Tablet, enteric coated 18,087,352 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
C03CA01 FUROSETIC G Furosemide - 40mg 40mg Tablet, scored 121,586 L.L
C09CA01 LOSANET G Losartan potassium - 100mg 100mg Tablet 395,474 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,127,484 L.L
D07CC01 ZETA-CORT G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 244,579 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg 625mg Tablet, film coated 402,189 L.L
J01GB03 GENTAMICINE PANPHARMA G Gentamicin (sulfate) - 80mg/2ml 80mg/2ml Injectable solution 721,643 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 20mg 20mg Tablet, film coated 103,165,573 L.L
M01AB05 DICLO-DENK 100 RECTAL G Diclofenac sodium - 100mg 100mg Suppository 310,428 L.L
P01AB01 METRIS G Metronidazole - 500mg/100ml 0.5% Injectable solution 142,447 L.L
R05DA20 ALGOMIEL COUGH SYRUP G Dextromethorphan HBr - 5mg, Carbinoxamine maleate - 2mg Syrup 639,925 L.L
S03AA07 API-CIPROCIN G Ciprofloxacine (HCl) - 3mg/ml 3mg/ml Drops 530,818 L.L
A02BC01 OMEPRAL G Omeprazole - 20mg 20mg Capsule, delayed release 213,735 L.L
A10BJ06 SEMATIDE G Semaglutide - 1mg 1mg Injectable solution 9,288,397 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
    ...
    84
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025